Large-Scale Human Cell Bank and Pharmaceutical Company Customer Base
First written in FY2017-Q1. 6 of 7 entries say "Restated". Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026RestatedAnnual report
「REPROCELL USA owns a bank of approximately 600,000 human biological specimens, including cancer cells, blood and serum, and provides them mainly to pharmaceutical companies as research materials.」
Reaffirming the US subsidiary's approximately 600,000-sample human biological specimen bank and its platform for supplying pharmaceutical companies. - FY2023-Q3RestatedAnnual report
「Our US subsidiary owns a large biological specimen bank and provides these biological specimens to pharmaceutical companies worldwide.」
Reaffirming the large biological specimen bank of the US subsidiary and its platform for supplying pharmaceutical companies worldwide. - FY2023-Q2RestatedAnnual report
「Our US subsidiary owns a large biological specimen bank and provides these biological specimens to pharmaceutical companies worldwide.」
Reaffirming the large biological specimen bank of the US subsidiary and its platform for supplying pharmaceutical companies worldwide. - FY2023-Q1RestatedAnnual report
「Our US subsidiary owns a large biological specimen bank and provides these biological specimens to pharmaceutical companies worldwide.」
Reaffirming the large biological specimen bank of the US subsidiary and its platform for supplying pharmaceutical companies. - FY2021RestatedAnnual report
「REPROCELL USA owns a bank of 600,000 human biological samples, including cancer cells, blood and serum, and provides them as research materials, primarily to pharmaceutical companies.」
Reaffirming the 600,000-sample human biological specimen bank and the platform for supplying pharmaceutical companies. - FY2020RestatedAnnual report
「REPROCELL USA owns a bank of 600,000 human biological samples, including cancer cells, blood and serum, and provides them as research materials, primarily to pharmaceutical companies.」
Reaffirming the 600,000-sample human biological specimen bank and the platform for supplying pharmaceutical companies. - FY2017-Q1First statedAnnual report
「The Group owns a bank containing more than 600,000 types of cells and serves a broad range of customer needs.」
A business foundation data point showing the breadth of the human cell offering. It also states that the company has 8 of the 10 largest pharmaceutical companies worldwide as customers.